Skip to main content

Xenomics Changes Name to TrovaGene

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – San Diego-based Xenomics has changed its name to TrovaGene and its ticker symbol to TROV, effective yesterday.

The firm is developing molecular diagnostics based on its transrenal nucleic acid technology. TrovaGene said that it has leased a 5000-square-foot facility in the Sorrento Valley area of San Diego and is in the process of completing all the necessary laboratory validations. The firm added that it plans to expand its scientific team as it works toward becoming a fully integrated diagnostic business by the end of the second quarter of this year.

Among the products TrovaGene has in development are a KRAS assay and an assay for human papillomavirus genotypes.

TrovaGene's shares currently trade at $.59 on the Pink Sheets.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.